Study protocol
One hundred and forty post-renal transplant patients hospitalized at the
Third People’s Hospital of Shenzhen for COVID-19 and treated using
small-molecule antivirals between December 2022 and January 2023 were
included. Patients were divided into azvudine, paxlovid, and azvudine +
paxlovid (A+P) groups, according to their treatment status. By comparing
the general condition, immunomodulatory treatment, clinical regression,
and occurrence of adverse outcomes, such as death, ICU admission, and
graft inactivation between the different treatment groups, we provided
insights into the management of the novel coronavirus-related pneumonia
in patients after kidney transplantation.
This study was strictly conducted per the guidelines of the Declaration
of Helsinki of the World Medical Association (2000), and it was approved
and supervised by the ethics committee of the Third People’s Hospital of
Shenzhen (approval number 2023-036-02).